Agenus Inc (AGEN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$8.240.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · AGEN
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 132.7 | 114.2 | 103.5 | 156.3 | 98.0 | 295.7 | 88.2 | 150.0 | 36.8 | 42.9 | 22.6 | 24.8 | 7.0 | 3.0 | 16.0 | 2.8 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 42.9 | 22.6 | 24.8 | 7.0 | 3.0 | 16.0 | 2.8 |
| Cost of Revenues | — | 1.0 | 0.5 | 3.1 | 10.6 | 3.5 | 2.3 | — | — | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| R&D Expenses | 57.7 | 79.3 | 155.5 | 234.6 | 186.7 | 178.6 | 142.6 | 168.3 | 124.6 | 116.1 | 95.0 | 70.4 | 22.3 | 13.0 | 10.6 | 11.0 |
| Operating Income | 36.2 | (20.2) | (120.5) | (159.5) | (179.4) | 25.7 | (117.2) | (70.1) | (123.8) | (103.8) | (107.5) | (80.7) | (43.3) | (25.0) | (6.7) | (19.1) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 55.6 | 120.4 | — | — | — | — | — | — | — | — | — | 1.3 | 2.4 | 4.7 | 4.2 |
| Interest & Investment Income | 0.2 | 0.3 | 2.8 | 5.9 | 2.3 | — | — | — | — | — | — | — | — | 0.0 | 0.0 | — |
| Net Interest Expenses | — | — | — | — | — | — | — | — | — | — | — | — | — | 2.4 | 4.7 | — |
| Other Non-Operating Income / Expenses | (1.3) | (2.2) | 5.8 | 0.0 | 12.6 | 5.1 | (1.9) | 0.0 | (2.2) | 2.0 | (2.2) | (6.0) | 2.1 | (2.7) | 0.1 | 0.0 |
| Asset Writedown | — | 0.2 | 2.0 | 0.0 | 6.1 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — | — | — | 0.0 | — |
| EBT, Incl. Unusual Items | — | (3.1) | — | (257.4) | — | — | — | — | — | (120.7) | (127.0) | (93.3) | — | — | — | — |
| Income Tax Expense | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (5.4) | 0.0 | 0.0 | — | — |
| Net Income | ||||||||||||||||
| Minority Interest | (0.1) | (3.2) | (5.1) | (11.7) | (10.6) | (4.8) | (2.0) | (3.9) | (2.4) | — | — | — | — | — | — | — |
| Net Income | — | (3.1) | (232.3) | (257.4) | (230.7) | (28.7) | (182.9) | (111.6) | (162.0) | (120.7) | (127.0) | (87.9) | (42.5) | (30.1) | (11.3) | (23.3) |
| Per Share | ||||||||||||||||
| Basic EPS | — | 0.00 | (10.59) | (13.75) | (15.64) | (0.11) | (1.05) | — | — | — | — | — | — | — | — | — |
| Diluted EPS | — | 0.00 | (10.59) | (13.75) | (15.64) | (0.11) | (1.05) | — | — | — | — | — | — | — | — | — |
| Revenue per Share | 3.21 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 41.3 | 29.7 | 21.5 | 17.9 | 14.1 | 0.2 | 0.2 | — | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 41.3 | 29.7 | 21.5 | 17.9 | 14.1 | 0.2 | 0.2 | — | — | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | (10.2) | (107.1) | (146.0) | (172.5) | 32.5 | (110.1) | (63.5) | (117.5) | (97.8) | (102.5) | (78.7) | (41.7) | (24.4) | (5.1) | (16.8) |
| EBIT | 36.2 | (20.2) | (120.5) | (159.5) | (179.4) | 25.7 | (117.2) | (70.1) | (123.8) | (103.8) | (107.5) | (80.7) | (43.3) | (25.0) | (6.7) | (19.1) |
| Effective Tax Rate | — | — | — | 0.0% | — | — | — | — | — | 0.0% | 0.0% | 5.8% | — | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.